News and Press Releases
Press releases
Theralase Grants Stock Options
Press ReleaseToronto, Ontario – April 18, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the devel...
Theralase PDT Technology Used to Treat Second Patient for Bladder Cancer
Press ReleaseToronto, Ontario – April 18, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the de...
Theralase Affiliated Researchers to Present at International Conference
Press ReleaseToronto, Ontario – April 12, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the devel...
Theralase Announces Acceptance of Peer Reviewed Publication for Next Generation Anti-Cancer Drugs
Press ReleaseToronto, Ontario – April 6, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the develo...
Theralase PDT Technology Used to Treat First Patient for Bladder Cancer
Press ReleaseToronto, Ontario – April 4, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the de...
Theralase Demonstrates 18 Month Stability of Lead Anti-Cancer Drug
Press ReleaseToronto, Ontario – March 15, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the deve...
Health Canada Approves Clinical Trial Application for Anti-Cancer Drug
Press ReleaseToronto, Ontario – December 17, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and...
Theralase Releases AGM Presentation Video
Press ReleaseToronto, Ontario – December 14, 2016, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the ...
Theralase Adopts Advance Notice By-Law
Press ReleaseToronto, Ontario – December 13, 2016 – Theralase Technologies Inc. (“Theralase” or the “Corporation”) (TLT: TSXV) (TLTFF: OTC) today announced that its board of directors (“Board“) has adopted By-Law No. 3 (“By-Law”) to est...
Theralase Demonstrates 12 Month Stability of Lead Anti-Cancer Drug
Press ReleaseToronto, Ontario – November 30, 2016, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the ...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
